Absence of gargling affects topical adverse symptoms caused by inhaled corticosteroids in females

Journal of Asthma

Volumn 51, Issue 2, 2014, Pages 221-224

  Kajiwara, Ayami ^a   Kita, Ayana ^a   Saruwatari, Junji ^a   Morita, Kazunori ^a   Oniki, Kentaro ^a   Yamamura, Masato ^b   Murase, Motoji ^b   Koda, Haruo ^b   Hirota, Seisuke ^b   Ishizuka, Tadao ^a   Nakagawa, Kazuko ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b Kumamoto Medical Association   (Japan)

Author keywords

Adverse drug reactions; Dry powder inhaler; Dysphonia; Gargle; Gender difference; Inhaled corticosteroid

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUTICASONE PROPIONATE; MOMETASONE FUROATE;

ADULT; AEROSOL; AGED; ARTICLE; ASTHMA; CONTROLLED STUDY; DISEASE ASSOCIATION; DRY POWDER INHALER; FEMALE; GOLD STANDARD; HEALTH SURVEY; HOARSENESS; HUMAN; INCIDENCE; INHALATION SPACER; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUTH HYGIENE; PHARMACIST; RISK FACTOR; SELF CONCEPT; SEX DIFFERENCE; STOMATITIS; STRUCTURED QUESTIONNAIRE; VERY ELDERLY; XEROSTOMIA;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; AGED, 80 AND OVER; ANTI-ASTHMATIC AGENTS; ASTHMA; FEMALE; HOARSENESS; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; ORAL HYGIENE; RISK FACTORS; STOMATITIS; YOUNG ADULT;

EID: 84894483531     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.857683     Document Type: Article

References (24)

1. Chhabra SK, Chhabra P. Gender differences in perception of dyspnea, assessment of control and quality of life in asthma. J Asthma 2011;48:609-615
2. Lux R, Awa W, Walter U. An interdisciplinary analysis of sex and gender in relation to the pathogenesis of bronchial asthma. Respir Med 2009;103:637-649
3. Choi IS. Gender-specific asthma treatment. Allergy Asthma Immunol Res 2011;3:74-80
4. Foster JM, Van Sonderen E, Lee AJ, Sanderman R, Dijkstra A, Postma DS, Van Der Molen T. A self-rating scale for patientperceived side effects of ICS. Respir Res 2006;7:131
5. Galvan CA, Guarderas JC. Practical considerations for dysphonia caused by ICS. Mayo Clin Proc 2012;87:901-904
6. Saruwatari J, Matsunaga M, Ikeda K, Nakao M, Oniki K, Seo T, Mihara S, et al. Impact of CYP2D6. *10 on H1-Antihistamineinduced hypersomnia. Eur J Clin Pharmacol 2006;62:995-1001
7. Temprano J, Mannino DM. The effect of sex on asthma control from the National Asthma Survey. J Allergy Clin Immunol 2009; 123:854-860
8. Williamson IJ, Matusiewicz SP, Brown PH, Greening AP, Crompton GK. Frequency of voice problems and cough in patients using pressurized aerosol inhaled steroid preparations. Eur Respir J 1995;8:590-592
9. Lipworth BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacol Ther 1993;58:173-209
10. Rachelefsky GS, Liao Y, Faruqi R. Impact of inhaled corticosteroid- induced oropharyngeal adverse events: Results from a metaanalysis. Ann Allergy Asthma Immunol 2007;98:225-238
11. Brown PH, Blundell G, Greening AP, Crompton GK. Do large volume spacer devices reduce the systemic effects of high dose ICS? Thorax 1990;45:736-739
12. Konig P. Spacer devices used with metered-dose inhalers. Breakthrough or gimmick? Chest 1985;88:276-284
13. Van Boven JF, De Jong-van Den Berg LT, Vegter S. ICS and the occurrence of oral candidiasis: A prescription sequence symmetry analysis. Drug Saf 2013;36:231-236
14. Holgate S, Bisgaard H, Bjermer L, Haahtela T, Haughney J, Horne R, McIvor A, et al. The Brussels Declaration: The need for change in asthma management. Eur Respir J 2008;32:1433-1442
15. Molimard M, Le Gros V, Robinson P, Bourdeix I. Prevalence and associated factors of oropharyngeal side effects in users of ICS in a real-life setting. J Aerosol Med Pulm Drug Deliv 2010;23:91-95
16. Bhalla RK,Watson G, TaylorW, Jones AS, Roland NJ. Prospective, randomized cross-over trial to assess the ability of a DPI to reverse the local side effects of pressurized metered-dose inhalers. J Asthma 2008;45:814-819
17. Kajiwara A, Saruwatari J, Sakata M, Morita K, Kita A, Oniki K, Yamamura M, et al. Risk Factors for adverse symptoms during dipeptidyl peptidase-IV inhibitor therapy: Aquestionnaire-based study carried out by the JPA DEM Project in Kumamoto Prefecture. Drug Saf 2013;36:981-987
18. Nave R, Mueller H. From inhaler to lung: Clinical implications of the formulations of ciclesonide and other ICS. Int J Gen Med 2013; 6:99-107
19. Huang J, Shen H, Takahashi M, Fukunaga T, Toga H, Takahashi K, Ohya N. Pharyngeal cross-sectional area and pharyngeal compliance in normal males and females. Respiration 1998;65:458-468
20. Bergdahl M. Salivary flow and oral complaints in adult dental patients. Community Dent Oral Epidemiol 2000;28:59-66
21. Zitzmann NU, Schilling J, Weiger R, Pastoret MH, Loretan P. Gender-specific dental health issues and treatment considerations. Int J Prosthodont 2007;20:360-368
22. Saito J, Sato S, Fukuhara A, Sato Y, Nikaido T, Inokoshi Y, Fukuhara N, et al. Association of asthma education with asthma control evaluated by asthma control test, FEV1, and fractional exhaled nitric oxide. J Asthma 2013;50:97-102
23. Peters SP, Prenner BM, Mezzanotte WS, Martin P, OBrien CD. Long-Term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 2008;29:499-516
24. Yokoyama H, Yamamura Y, Ozeki T, Iga T, Yamada Y. Effects of mouth washing procedures on removal of budesonide inhaled by using Turbuhaler. Yakugaku Zasshi 2007;127:1245-1249 Technology